The widespread introduction of artemisinin-based combination therapy has contributed to recent reductions in malaria mortality. Combination therapies have a range of advantages, including synergism, toxicity reduction, and delaying the onset of resistance acquisition. Unfortunately, antimalarial combination therapy is limited by the depleting repertoire of effective drugs with distinct target p...

This introduction to the R package mixlow is a (slightly) modified version of Boik and Narasimhan (2010), published in the Journal of Statistical Software. Synergistic and antagonistic drug interactions are important to consider when developing mixtures of anticancer or other types of drugs. Boik, Newman, and Boik (2008) proposed the MixLow method as an alternative to the Median-Effect method o...

BACKGROUND Brain tumor-initiating cells (BTICs) are stem-like cells hypothesized to form a disease reservoir that mediates tumor recurrence in high-grade gliomas. Oncolytic virotherapy uses replication-competent viruses to target and kill malignant cells and has been evaluated in clinic for glioma therapy with limited results. Myxoma virus (MyxV) is a safe and highly effective oncolytic virus (...

The quinazoline folate analogue raltitrexed (ZD1694; Tomudex) and the camptothecin derivative irinotecan are two new agents showing clinical activity against colorectal cancer. To identify the optimal conditions to achieve synergistic cytotoxicity before the clinical development of their combination, we explored the interactions between ZD1694 and the active metabolite of irinotecan, 7-ethyl-10...

BACKGROUND Cordycepin requires the relatively toxic co-drug, deoxycoformycin, for full efficacy as an anticancer agent. We sought to improve cordycepin efficacy using other, less toxic co-drugs. MATERIALS AND METHODS We evaluated the ability of hydroxyurea (HU) to enhance the effects of cordycepin against MOLT-4 leukemia cells with the MTT cell viability assay. We determined the relationship ...

Abstract AIMS Synergistic combinations of doxorubicin and gemcitabine have been assessed for post-surgical treatment IDH1 wild-type glioblastoma (GBM). As a complementary drug carrier, hyperbranched micellar nanoparticles are being investigated to enable enhanced loading sustained release. METHOD 2D 3D spheroid in vitro models generated from patient-derived cells resected tumour core invasive m...

Abstract Background Inhibition of nuclear import via Karyopherin beta 1 (Kpnβ1) shows potential as an anti-cancer approach. This study investigated the use inhibitor, INI-43, in combination with cisplatin. Methods Cervical cancer cells were pre-treated INI-43 before treatment cisplatin, and MTT cell viability apoptosis assays performed. Activity localisation p53 NFκB was determined after co-tre...

Cutaneous T-cell lymphoma (CTCL) is a non-Hodgkin that presents with skin manifestations and often incurable at advanced stages blood involvement. Genomic profiling of malignant cells from CTCL patients has revealed diverse range genetic mutations underlying the disease, including single nucleotide gene copy number alterations involving JAK/STAT NF-κB signaling pathways. Synergistic drug combin...

PURPOSE To investigate whether celastrol could show synergism combined with lapatinib in HepG2 human hepatocellular carcinoma (HCC) cell line in vitro. METHODS The effects of treatment with lapatinib and/or celastrol on cell growth were determined using MTT assay. Drug synergy was determined using combination index (CI) methods derived from Chou-Talalay equations using CalcuSyn software. Apop...